Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7974655 | 0.78 | AMPD2 (0.41) | MEN1KMT2ALMNATDP1SMN1; SMN2 | |
| SCHEMBL21962295 | 0.78 | MEN1 (0.38) | MEN1KMT2AALDH1A1DUTCYP1A2 | |
| SCHEMBL28578994 | 0.76 | MEN1 (0.49) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL24810046 | 0.75 | KMT2A (0.44) | MEN1KMT2ALMNAATM | |
| SCHEMBL6293 | 0.75 | MAPT (0.46) | MAPTMEN1KMT2ALMNANPSR1 | |
| SCHEMBL20139750 | 0.73 | KMT2A (0.45) | TARBP2MAPTMEN1KMT2ALMNA | |
| SCHEMBL6625123 | 0.73 | POLB (0.41) | MAPTMEN1KMT2ALMNAMAPK1 | |
| SCHEMBL23485806 | 0.73 | CYP2C19 (0.41) | LMNAMAPK1CYP2C19SMN1; SMN2ATM | |
| SCHEMBL30243990 | 0.72 | MAPT (0.41) | MAPTMEN1KMT2ALMNAMAPK1 | |
| SCHEMBL28782325 | 0.72 | ADRB2 (0.41) | MAPTKMT2ALMNAALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202866-B2 | Ortho-aminoanilides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202866-B2 | Ortho-aminoanilides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2334658-A2 | ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010031708-A2 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | IL4I1, MKI67, ABL1 | TARBP2 4840/4885MAPT 4110/4885MEN1 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.